Skip to main content
. 2021 Apr 1;10(4):373. doi: 10.3390/antibiotics10040373

Table 2.

Summary of comparative studies evaluating D-mannose administration.

Author,
Year		 Study
Design		 Study
Population		 Inclusion
Criteria		 Treatment Main
Results
Kranjcec et al.,
2014		 Randomized 308 Women
18–75 years		 Recurrent UTIs
  • -

    D-mannose

  • -

    Nitrofurantoin

  • -

    None

 D-mannose (15%) and Nitrofurantoin (20%) groups presented a lower risk of UTIs when compared to controls (61%).
Porru,
2014		 Randomized 60 Women Recurrent UTIs
  • -

    Trimetoprim/Sulfamethoxazole

  • -

    D-mannose

 Mean time to UTI
52 vs. 200 days favors D-mannose
Palleschi,
2017		 Randomized 42 Men and 38 Women Post Urodynamic
  • -

    D-mannose, N-acetylcisteintand Morinda citriofula

  • -

    Antibiotic

 No difference in terms of UTis post- urodynamics.
De Leo
2017		 Randomized 150 Women Recurrent UTIs
  • -

    Kistinox (Carnberry, Propolis, D-Mannose)

  • -

    No treatment

 Reduction of dysuria and frequency.
Salinas-Casado
2018		 Randomized 150 Women Recurrent UTIs
  • -

    D-mannose 2 g + PAC 140 mg

  • -

    PAC 240 mg

 95 days vs. 79 days disease-free favor the D-mannose group.
Salinas-Casado
2020		 Randomized 184 Women Recurrent UTIs
  • -

    D-mannose 2 g

  • -

    PAC 240 mg

 27% vs. 50% of UTIs favors the D-mannose group.

PAC: proanthocyanidins.